There were 1,662 press releases posted in the last 24 hours and 468,226 in the last 365 days.

M2Bio Sciences Signs MMA EFC Pro Fighter Luke “Young Gun” Michael

EFC Luke "Young Gun" Michael

M2Bio, Luke "Young Gun" Michael, EFC

Institute of Biomedical Research (OTCBB:MRES)

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, January 27, 2023 / -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a biotechnology company focused on alternative plant-based cannabinoids and mental health clinical research is pleased to share the following update:

M2Bio Sciences is pleased to announce a new Brand Ambassador has joined the Health and Fitness team. Luke "Young Gun" Michael is a professional Mixed Martial Arts fighter with the Extreme Fighting Championship (EFC), Africa's largest MMA promotion company. He is the current middleweight title holder. His experience in MMA has led him to acquire unique knowledge in health and fitness, which will assist in driving the M2Bio Sport & Fitness division's culture of mental, nutritional, and physical well-being. The division is headed up by M2Bio Sciences Director of Sports and Fitness, EFC MMA athlete Robert "The Black Tiger” Simbowe.

Luke “Young Gun” Michael was born and raised in Goodwood, Cape Town. From a young age he’s been determined to be an MMA Fighter and now this promising athlete will be joining the M2Bio Fitness and Health Ambassador Team. His words before his winning match at EFC 92 against Pupanga Tresor in March 2022 were: “This fight is my life, it’s everything to me. It’s all I have and I have to win.”

"In addition to being the current belt holder, Luke is an individual of great character, always looking for ways to help others achieve their goals in life. Proud to have him in the M2Bio Sciences family" - said Jeff Robinson, CEO M2Bio Sciences.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “MRES”.
Publicly traded company (OTC Pink:MRES)


Find us on social media
Instagram: m2bio.sciences
Facebook: M2Bio Sciences
LinkedIn: M2Bio Sciences, Inc.

Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Jeff Robinson
M2Bio Sciences Food and Beverage (Pty) Ltd
27 72 333 2148
email us here